Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Cancer Management and Research|November 12, 2021
Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in ChinaYamin Shu, Qilin Zhang, Xucheng He, et al.
Frontiers in Oncology|December 20, 2021
Cost-Effectiveness Analysis of Camrelizumab <i>vs.</i> Placebo Added to Chemotherapy as First-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in ChinaQilin Zhang, Pan Wu, Xucheng He, et al.
Frontiers in Pharmacology|April 4, 2022
Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Associated Cardiotoxicity: A Recent Five-Year Pharmacovigilance StudyYihan Liu, Chen Chen, Chencheng Rong, et al.
Clinical Epidemiology|July 5, 2022
A Real-World Disproportionality Analysis of Olaparib: Data Mining of the Public Version of FDA Adverse Event Reporting SystemYamin Shu, Xucheng He, Yanxin Liu, et al.
Frontiers in Pharmacology|August 29, 2022
Cost-effectiveness analysis of olaparib as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation in chinaYamin Shu, Yanxin Liu, Xucheng He, et al.
The Journal of Physical Chemistry. A|August 11, 2017
Computational and Experimental Investigation of the Detection of HO<sub>2</sub> Radical and the Products of Its Reaction with Cyclohexene Ozonolysis Derived RO<sub>2</sub> Radicals by an Iodide-Based Chemical Ionization Mass SpectrometerSiddharth Iyer, Xucheng He, Noora Hyttinen, et al.
Journal of Pharmacy & Pharmaceutical Sciences : a Publication of the Canadian Society for Pharmaceutical Sciences, Societe Canadienne Des Sciences Pharmaceutiques|January 7, 2023
Post-Marketing Safety of Vemurafenib: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting SystemYanxin Liu, Changjiang Dong, Xucheng He, et al.
Frontiers in Pharmacology|September 23, 2022
Fluoroquinolone-associated suspected tendonitis and tendon rupture: A pharmacovigilance analysis from 2016 to 2021 based on the FAERS databaseYamin Shu, Qilin Zhang, Xucheng He, et al.
Cancer Medicine|July 24, 2022
Hematological toxicities in PARP inhibitors: A real-world study using FDA adverse event reporting system (FAERS) databaseYamin Shu, Yufeng Ding, Xucheng He, et al.
Frontiers in Pharmacology|October 7, 2022
Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer in ChinaYamin Shu, Yufeng Ding, Xucheng He, et al.
Pageof 3